These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8263316)
1. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Montgomery SA; Rasmussen JG; Tanghøj P Int Clin Psychopharmacol; 1993; 8(3):181-8. PubMed ID: 8263316 [TBL] [Abstract][Full Text] [Related]
2. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Robert P; Montgomery SA Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():29-35. PubMed ID: 7622809 [TBL] [Abstract][Full Text] [Related]
4. Efficacy in long-term treatment of depression. Montgomery SA J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360 [TBL] [Abstract][Full Text] [Related]
5. Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. Singer A; Schmidt M; Hauke W; Stade K Phytomedicine; 2011 Jun; 18(8-9):739-42. PubMed ID: 21514125 [TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Mendels J; Kiev A; Fabre LF Depress Anxiety; 1999; 9(2):54-60. PubMed ID: 10207659 [TBL] [Abstract][Full Text] [Related]
7. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Hochstrasser B; Isaksen PM; Koponen H; Lauritzen L; Mahnert FA; Rouillon F; Wade AG; Andersen M; Pedersen SF; Swart JC; Nil R Br J Psychiatry; 2001 Apr; 178():304-10. PubMed ID: 11282808 [TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial. Phillips KA; Keshaviah A; Dougherty DD; Stout RL; Menard W; Wilhelm S Am J Psychiatry; 2016 Sep; 173(9):887-95. PubMed ID: 27056606 [TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Alexopoulos GS; Canuso CM; Gharabawi GM; Bossie CA; Greenspan A; Turkoz I; Reynolds C Am J Geriatr Psychiatry; 2008 Jan; 16(1):21-30. PubMed ID: 17928573 [TBL] [Abstract][Full Text] [Related]
10. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920 [TBL] [Abstract][Full Text] [Related]
11. Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. Franchini L; Zanardi R; Gasperini M; Smeraldi E J Clin Psychiatry; 1999 Dec; 60(12):861-5. PubMed ID: 10665634 [TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury. Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723 [TBL] [Abstract][Full Text] [Related]
13. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Montgomery SA; Dunbar G Int Clin Psychopharmacol; 1993; 8(3):189-95. PubMed ID: 8263317 [TBL] [Abstract][Full Text] [Related]
14. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Montgomery SA; Rasmussen JG Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():71-3. PubMed ID: 1431025 [No Abstract] [Full Text] [Related]
15. Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5). Licht RW; J Affect Disord; 2013 Jun; 148(2-3):286-90. PubMed ID: 23399479 [TBL] [Abstract][Full Text] [Related]
16. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Lepola UM; Wade AG; Leinonen EV; Koponen HJ; Frazer J; Sjödin I; Penttinen JT; Pedersen T; Lehto HJ J Clin Psychiatry; 1998 Oct; 59(10):528-34. PubMed ID: 9818634 [TBL] [Abstract][Full Text] [Related]
17. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Reimherr FW; Amsterdam JD; Quitkin FM; Rosenbaum JF; Fava M; Zajecka J; Beasley CM; Michelson D; Roback P; Sundell K Am J Psychiatry; 1998 Sep; 155(9):1247-53. PubMed ID: 9734550 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Colonna L; Andersen HF; Reines EH Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906 [TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Bauer M; Bschor T; Kunz D; Berghöfer A; Ströhle A; Müller-Oerlinghausen B Am J Psychiatry; 2000 Sep; 157(9):1429-35. PubMed ID: 10964859 [TBL] [Abstract][Full Text] [Related]
20. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Andersen G; Vestergaard K; Lauritzen L Stroke; 1994 Jun; 25(6):1099-104. PubMed ID: 8202964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]